Senhance at European Union

Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value.

The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable.

On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.